Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OABI vs MXCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MXCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 2–6 Matrix Metrics)
MXCT Overall Winner
6-Pillar Tally: OABI 2 – 3 MXCT (1 Tie)
Matrix Metrics: OABI 6 – 2 MXCT
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).
- Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -92.9% operating margin) and revenue trajectory (+48.7% vs. +78.3% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OABI vs MXCT
OABI
OmniAb, Inc. Common Stock
$4.66
-7.36% 1D
Market Cap
$733.7M
TTM Revenue
$40M
Forward P/E
N/M
Beta / 30D Vol
1.24β · 60% Vol
Unified Composite Score
45.5
HOLD
Tech 15.0
Fund 40.0
Flow 58.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
MXCT
Head-to-Head Winner
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (OABI 2 – 3 MXCT)
1. Valuation Multiples
MXCT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
18.1x
3.9x
2. Growth & Scale
OABI
Revenue Growth (YoY)
+78.3%
+48.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$40M
$34M
Market Cap
$733.7M
$132.2M
3. Profitability & Quality
MXCT
Gross Margin
97.7%
81.0%
Operating Margin
-92.9%
-85.5%
Net Profit Margin
-108.1%
-81.4%
Return on Equity (ROE)
-16.5%
-16.9%
4. Balance Sheet & Cash Flow
OABI
Cash Generation (TTM)
$2.4M
-$24M
Cash Flow Margin
5.9%
-69.2%
Net Cash / Leverage
$4.7M Net Cash
$2.2M Net Debt (0.11x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MXCT
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
101.7% (14th %ile)
N/A (N/A)
Put/Call OI Skew
0.04x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OABI (6) vs MXCT (2)| Institutional Metric | OABI | MXCT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $733.7M | $132.2M | OABI | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +78.3% | +48.7% | OABI | |
| Operating Margin (TTM) | -92.9% | -85.5% | MXCT | |
| Net Profit Margin | -108.1% | -81.4% | MXCT | |
| Return on Equity (ROE) | -16.5% | -16.9% | OABI | |
| 52-Week Range Position | 81% ($1–$5) | 63% ($1–$2) | OABI | |
| Beta / 30D Volatility | 1.24β · 60% Vol | 1.19β · 96% Vol | OABI | |
| Unified Institutional Score | 45.5 / 100 (HOLD) | 41.7 / 100 (SELL) | OABI | |
| Trailing 12M Revenue (USD) | $40M | $34M | Scale | |
| Gross Profit Margin (TTM) | 97.7% | 81.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 18.1x EV/Rev | N/M PEG · 3.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $2.4M ($4.7M Net Cash) | -$24M ($2.2M Net Debt (0.11x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OABI +1.69 pp
3M Horizon
OABI +0.38 pp
6M Horizon
OABI +44.12 pp
1Y Horizon
OABI +201.83 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OABI Revenue | MXCT Revenue | OABI Op. Margin | MXCT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -93.7% | MXCT |
| FY2020 | N/A | $20M | N/A | -71.6% | MXCT |
| FY2021 | $30M | $20M | -102.5% | -84.3% | MXCT |
| FY2022 | $60M | $30M | -45.1% | -95.2% | OABI |
| FY2023 | $30M | $20M | -203.2% | -247.7% | OABI |
| FY2024 | $30M | $20M | -282.3% | -230.5% | MXCT |
| FY2025 | $20M | $20M | -369.5% | -247.6% | MXCT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OABI
CONSOLIDATION
Current IV
101.7%
IV Percentile
14th %ile
Put/Call OI Skew
0.04x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OABI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OABI vs MXCT Key Questions & Quantitative Answers
As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -92.9% operating margin) and revenue trajectory (+48.7% vs. +78.3% YoY).
OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), OABI cumulative revenue shifted -33.3% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.
MXCT screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.1x EV/Revenue (5.9% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus MXCT (-16.9% ROE) capital efficiency.
In options market volatility and institutional positioning, OABI carries 101.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 60% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MXCT vs OABI · Reverse Pair
OABI vs OBIO
· Sector Peer
OABI vs LRMR
· Sector Peer
OABI vs PEPG
· Sector Peer
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem